Breast Cancer

Findings from the POSITIVE trial suggest that pausing endocrine therapy to pursue pregnancy did not negatively affect outcomes for patients with breast cancer.

A landmark 4-year analysis of invasive-disease free survival outcomes from the phase 3 monarchE study support the use of adjuvant abemaciclib with endocrine therapy for patients with hormone receptor–positive, HER2-negative, node-positive early breast cancer.

Trastuzumab deruxtecan both significantly improved overall survival and yielded progression-free survival that was 4 times greater than trastuzumab emtansine in patients with HER2-positive metastatic breast cancer.

New findings suggest that neoadjuvant therapy with antibody-drug conjugates may be effective for patients with early-stage breast cancer.

Improve care for LGBTQ+ patients with cancer by learning about disparities, focusing on patient-centered treatment, and not making assumptions about patients and their loved ones.

Disease-free survival in patients with metastatic breast cancer did not differ between treatment with everolimus or placebo.

Margetuximab did not deliver a significant survival benefit in patients with HER2-positive advanced breast cancer compared with trastuzumab.

The 1-year PFS rate among patients with metastatic, triple-negative breast cancer who received a combination eganelisib, atezolizumab, and nab-paclitaxel was 36%.

Oncology nurses are in a unique position to educate patients with breast cancer about post-mastectomy chest numbness.

Manmeet Ahulwalia, MD, MBA, underscores how novel treatment approaches in oncology are proving effective in managing brain metastases.

During the 40th Annual Chemotherapy Foundation Symposium®, Hope S. Rugo, MD, FASCO, outlined key priorities for the future of breast cancer research.

Immunotherapy has changed the face of cancer treatment, but requires appropriate irAE management to reach full potential.

After demonstrating significant efficacy as a third-line treatment for patients with metastatic HER2-positive breast cancer, fam-trastuzumab deruxtecan-nxki has gained approval from the FDA for 5 indications and is under investigation across solid tumors.

The rate of severe radiation dermatitis was reduced with the use of Mepital Film in patients with breast cancer undergoing mastectomy.

Patients with HER2-positive breast cancer and brain metastases experienced a median progression-free survival of 8 months and a median overall survival of 14 months with HER2-targeted therapy.

Liz-Hunter Brack, RN, discusses how oncology nurses can play an important role in patient education surrounding genetic testing.

Sri Kota, MSN, BA, RN, OCN, unpacks data from the phase 3 TROPiCS-02 trial and highlights what nurses should know about sacituzumab govitecan for patients with advanced hormone receptor–positive, HER2-negative breast cancer.

Katie Couric is educating the public about the importance of ultrasounds for women with dense breasts.

At a follow-up of 60-months, investigators found that breast cancer survivors with higher C-reactive protein counts reported worse cognitive function over time.

Olaparib is an oral drug manufactured in 150-mg and 100-mg tablets. Olaparib is taken by mouth, twice daily. It can be taken without or without food.

HER2-directed antibody-drug conjugates (ADCs) play an important role in the treatment of breast and gastric cancer.

Selpercatinib demonstrated a promising efficacy profile in patients with RET-fusion positive solid tumors.

Following promising efficacy data from the phase 3 TROPiCS-02 trial, the FDA has granted sacituzumab govitecan priority review status on the indication of HR+/HER2 metastatic breast cancer.

Shared practical advice on the management of toxicities associated with antibody drug conjugate therapy in both the breast cancer and GI cancer settings.

Before closing out their discussion on HER2+ gastric cancer, experts review clinical trials investigating other novel ADC agents in this setting.